{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:36:47Z","timestamp":1787240207749,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology, Transfusion and Cell Therapy"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.htct.2025.103962","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T04:15:05Z","timestamp":1757650505000},"page":"103962","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Overall survival in multiple myeloma in Brazil: A cohort of 16 years"],"prefix":"10.1016","volume":"47","author":[{"given":"Deborah Marta do Santos","family":"Oliveira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0674-8187","authenticated-orcid":false,"given":"Isabela Cristina Menezes","family":"de Freitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wallace Mateus","family":"Prata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Zuppo Laper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e2mela Santos","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano de Paula","family":"Sabino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa Yurico","family":"Itonaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8656-8374","authenticated-orcid":false,"given":"Carmino Antonio","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari\u00e2ngela Leal","family":"Cherchiglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana Alvares","family":"Teodoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco de Assis","family":"Acurcio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5256-0577","authenticated-orcid":false,"given":"Augusto Afonso Guerra","family":"Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.htct.2025.103962_bib0001","unstructured":"CDC. Myeloma [Internet]. [cited 2023 Oct 8]. Available from: https:\/\/www.cdc.gov\/cancer\/myeloma\/index.htm"},{"issue":"6","key":"10.1016\/j.htct.2025.103962_bib0002","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: a unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"issue":"5","key":"10.1016\/j.htct.2025.103962_bib0003","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.htct.2025.103962_bib0004","series-title":"Estimativa 2020: incid\u00eancia de c\u00e2ncer no Brasil \/Instituto Nacional de C\u00e2ncer Jos\u00e9 Alencar Gomes da Silva","year":"2019"},{"issue":"5","key":"10.1016\/j.htct.2025.103962_bib0005","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3324\/haematol.11637","article-title":"Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myeloma","volume":"93","author":"Hungria","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.htct.2025.103962_bib0006","unstructured":"INSTITUTE FOR HEALTH METRICS AND EVALUATION - IHME. GBD compare."},{"issue":"12","key":"10.1016\/j.htct.2025.103962_bib0007","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.htct.2025.103962_bib0008","series-title":"NCCN guidelines version 5.2022 multiple myeloma","year":"2022"},{"key":"10.1016\/j.htct.2025.103962_bib0009","series-title":"Relat\u00f3rio Conitec no 558: bortezomibe para o tratamento de pacientes adultos com mieloma m\u00faltiplo, n\u00e3o previamente tratados, eleg\u00edveis ao transplante aut\u00f3logo de c\u00e9lulas tronco hematopoi\u00e9ticas","year":"2020"},{"key":"10.1016\/j.htct.2025.103962_bib0010","series-title":"Relat\u00f3rio Conitec no 559: bortezomibe para o tratamento de pacientes adultos com mieloma m\u00faltiplo, n\u00e3o previamente tratados, ineleg\u00edveis ao transplante aut\u00f3logo de c\u00e9lulas-tronco hematopoi\u00e9ticas","year":"2020"},{"key":"10.1016\/j.htct.2025.103962_bib0011","unstructured":"BRASIL. Minist\u00e9rio da Sa\u00fade. Portaria no 708, de 06 de agosto de 2015. Aprova as Diretrizes Diagn\u00f3sticas e Terap\u00eauticas do Mieloma M\u00faltiplo. Available from:https:\/\/www.gov.br\/saude\/pt-br\/assuntos\/protocolos-clinicos-e-diretrizes-terapeuticas-pcdt\/arquivos\/2015\/ddt_mieloma-multiplo.pdf"},{"issue":"1","key":"10.1016\/j.htct.2025.103962_bib0012","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11239-023-02817-7","article-title":"Comparison of three risk assessment models for thromboembolism in multiple myeloma patients receiving immunomodulators: a Brazilian historical cohort","volume":"56","author":"da Costa","year":"2023","journal-title":"J Thromb Thrombol"},{"key":"10.1016\/j.htct.2025.103962_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2023.102377","article-title":"Real-world effectiveness and safety of multiple myeloma treatments based on thalidomide and bortezomib: a retrospective cohort study from 2009 to 2020 in a Brazilian metropolis","volume":"85","author":"Drummond","year":"2023","journal-title":"Cancer Epidemiol"},{"issue":"1","key":"10.1016\/j.htct.2025.103962_bib0014","article-title":"Building the National database of Health centred on the individual: administrative and epidemiological record linkage - Brazil, 2000-2015","volume":"3","author":"Junior","year":"2018","journal-title":"Int J Popul Data Sci"},{"issue":"3","key":"10.1016\/j.htct.2025.103962_bib0015","article-title":"Ricas SMM de C, Almeida EB de. Perfil epidemiol\u00f3gico de pacientes diagnosticados com mieloma m\u00faltiplo em hospital de refer\u00eancia para neoplasias malignas hematol\u00f3gicas","volume":"52","author":"Garcia","year":"2020","journal-title":"RRev Bras Hematol Hemoter"},{"issue":"2","key":"10.1016\/j.htct.2025.103962_bib0016","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1590\/S1516-84842009005000013","article-title":"Mieloma m\u00faltiplo: caracter\u00edsticas cl\u00ednicas e laboratoriais ao diagn\u00f3stico e estudo progn\u00f3stico","volume":"31","author":"Silva","year":"2009","journal-title":"Rev Bras Hematol Hemoter"},{"key":"10.1016\/j.htct.2025.103962_bib0017","series-title":"PNS 2013: tr\u00eas em cada quatro brasileiros costumam buscar atendimento m\u00e9dico na rede p\u00fablica de sa\u00fade","year":"2015"},{"issue":"1","key":"10.1016\/j.htct.2025.103962_bib0018","first-page":"3","article-title":"Epidemiology, staging, and management of Multiple myeloma","volume":"9","author":"Padala","year":"2021","journal-title":"Med Sci"},{"key":"10.1016\/j.htct.2025.103962_bib0019","series-title":"United States life tables","author":"Arias","year":"2021"},{"key":"10.1016\/j.htct.2025.103962_bib0020","series-title":"Em 2022, expectativa de vida era de 75,5 anos","year":"2023"},{"key":"10.1016\/j.htct.2025.103962_bib0021","first-page":"10","article-title":"Mieloma m\u00faltiplo no Brasil: aspectos cl\u00ednicos, demogr\u00e1ficos e valida\u00e7\u00e3o do Sistema de Estadiamento Internacional (ISS) em pacientes brasileiros","author":"Hungria","year":"2007","journal-title":"Rev Bras Hematol Hemoter"},{"key":"10.1016\/j.htct.2025.103962_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00676","article-title":"The role of immunotherapy in non-transplant eligible multiple myeloma","volume":"10","author":"Bobin","year":"2020","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.htct.2025.103962_bib0023","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nrclinonc.2011.63","article-title":"Treatment of multiple myeloma","volume":"8","author":"Rajkumar","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.htct.2025.103962_bib0024","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00277-016-2866-9","article-title":"Observational study of multiple myeloma in Latin America","volume":"96","author":"Hungria","year":"2017","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.htct.2025.103962_bib0025","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.3324\/haematol.2021.280424","article-title":"Improved survival in myeloma patients\u2013a nationwide registry study of 4647 patients \u226575 years treated in Denmark and Sweden","volume":"108","author":"Moore","year":"2022","journal-title":"Haematologica"},{"issue":"13","key":"10.1016\/j.htct.2025.103962_bib0026","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","article-title":"Bortezomib plus Melphalan and Prednisone compared with Melphalan and Prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial","volume":"28","author":"Mateos","year":"2010","journal-title":"J Clinic Oncol"},{"issue":"30","key":"10.1016\/j.htct.2025.103962_bib0027","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1200\/JCO.2016.66.7295","article-title":"Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or Melphalan, prednisone, and thalidomide in the randomized, phase III FIRST trial","volume":"34","author":"Hulin","year":"2016","journal-title":"J Clinic Oncol"},{"issue":"6","key":"10.1016\/j.htct.2025.103962_bib0028","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus Bortezomib, Melphalan, and Prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"New Engl J Med"},{"issue":"11","key":"10.1016\/j.htct.2025.103962_bib0029","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.htct.2025.103962_bib0030","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1182\/blood.V110.11.75.75","article-title":"Melphalan-Prednisone-Thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients \u226575 years with multiple myeloma compared with Melphalan-Prednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01\/01","volume":"110","author":"Hulin","year":"2007","journal-title":"Blood"},{"issue":"9594","key":"10.1016\/j.htct.2025.103962_bib0031","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99\u201306): a randomised trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.htct.2025.103962_bib0032","series-title":"Resolu\u00e7\u00e3o - Rdc No 34, De 20 de Abril De 2000","year":"2000"},{"issue":"10","key":"10.1016\/j.htct.2025.103962_bib0033","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.htct.2025.103962_bib0034","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1200\/JCO.2012.41.6180","article-title":"Persistent overall survival benefit and No increased risk of second malignancies with Bortezomib-Melphalan-Prednisone versus Melphalan-Prednisone in patients with previously untreated multiple myeloma","volume":"31","author":"San Miguel","year":"2013","journal-title":"J Clinic Oncol"},{"key":"10.1016\/j.htct.2025.103962_bib0035","series-title":"CONITEC. Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no sistema \u00fanico de Sa\u00fade","year":"2023"}],"container-title":["Hematology, Transfusion and Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137925002305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137925002305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T07:22:48Z","timestamp":1760858568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2531137925002305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2531137925002305"],"URL":"https:\/\/doi.org\/10.1016\/j.htct.2025.103962","relation":{},"ISSN":["2531-1379"],"issn-type":[{"value":"2531-1379","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overall survival in multiple myeloma in Brazil: A cohort of 16 years","name":"articletitle","label":"Article Title"},{"value":"Hematology, Transfusion and Cell Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.htct.2025.103962","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"103962"}}